High cost oncology drugs without proof of added benefit are burdening health systems

BMJ. 2024 Feb 29:384:q511. doi: 10.1136/bmj.q511.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Cost-Benefit Analysis
  • Drug Costs*
  • Humans
  • Medical Oncology*